Key statistics
On Friday, TScan Therapeutics Inc (TCRX:NMQ) closed at 5.52, 127.16% above the 52 week low of 2.43 set on Oct 02, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.62 |
---|---|
High | 5.62 |
Low | 5.44 |
Bid | 5.06 |
Offer | 5.66 |
Previous close | 5.64 |
Average volume | 197.67k |
---|---|
Shares outstanding | 52.97m |
Free float | 48.27m |
P/E (TTM) | -- |
Market cap | 292.42m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- TScan Therapeutics to Participate in Upcoming Investor Conferences
- TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces Updates to its Board of Directors
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
More ▼